top of page

Karus Therapeutics doses first lymphoma patients in Phase I KA2237 clinical study

The first patients have been dosed in a Phase I study for Karus Therapeutics‘ lead candidate, KA2237, their first product to enter clinical trials.

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page